Sign up to receive updates and resources about the treatment of presbyopia with YUVEZZI or request a sample for your practice and patients

Loading form…

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients.

WARNINGS AND PRECAUTIONS

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics. Advise patients to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal tear and detachment have been reported with miotics. Individuals with pre-existing retinal disease are at increased risk. Examination of the retina is advised in all patients prior to the initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

YUVEZZI is not recommended to be used when iritis is present.

Avoid touching the vial to the eye, eyelids, or to any other surface.

YUVEZZI may potentiate syndromes associated with vascular insufficiency.

DRUG INTERACTIONS

Antihypertensives/cardiac glycosides, tricyclic antidepressants, and monoamine oxidase inhibitors: caution advised.
CNS depressants: consider the possibility of additive or potentiating effects.

ADVERSE REACTIONS

The most common adverse reactions were eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache. The majority of adverse events were mild, transient, and self-resolving.

To report SUSPECTED ADVERSE REACTIONS, contact Visus Therapeutics, Inc., at 1-888-735-0821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional safety information, see the Full Prescribing Information.

INDICATION

YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1% is indicated for the treatment of presbyopia in adults.

Tenpoint Therapeutics, Ltd.

1200 Westlake Avenue North

Suite 600G

Seattle, WA 98109

GET UPDATES TERMS OF USE PRIVACY POLICY COOKIE POLICY SITE MAP

YUVEZZI and BRIO are trademarks of Visus Therapeutics, Inc. TENPOINT is a trademark of Tenpoint Therapeutics Holding Limited. Visus Therapeutics, Inc., an affiliate of Tenpoint Therapeutics, Ltd., Seattle,

Washington, 98109, MAT-US-YZ-0225 04/26

For US residents only.